Crispr TherapeutCH0334081137CRSPCRSP
Financials
Market Cap
$4.58B5Y beta
1.78EPS (TTM)
-$1.949Free Float
83.31MRevenue (TTM)
$371.21MEBITDA (TTM)
-$202.66MFree Cashflow (TTM)
-$272.35MPricing
Analyst Ratings
The price target is $85.88 and the stock is covered by 29 analysts.
Buy
14
Hold
11
Sell
4
Information
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.